Table 3A. Univariate and multivariable analysis of predictors of OS in the 69 patients with hyponatremia at the start of first-line therapy for locally advanced or metastatic NSCLC.
| OVERALL SURVIVAL IN HYPONATREMIC PATIENTS | ||||
|---|---|---|---|---|
| Univariate Cox Regression | Multivariable Cox regression | |||
| HR (95%CI) | p-value | HR (95%CI) | p-value | |
| Age (≥ 70y vs. < 70y) | 1.18 (0.64−2.20) | 0.598 | ||
| Gender (F vs. M) | 0.99 (0.54−1.84) | 0.990 | ||
| ECOG-PS (≥ 2 vs. < 2) | 1.29 (0.62−2.67) | 0.530 | ||
| Smoke status (N vs. Y) | 0.67 (0.23−1.64) | 0.462 | ||
| Tumor Stage (IV vs. III) | 2.59 (1.25−5.39) | 0.011 | 2.76 (1.31−5.81) | 0.008 |
| Histology (AC vs. non-AC) | 1.20 (0.69−2.08) | 0.520 | ||
| EGFR Status (MT vs. WT) | 0.90 (0.22−3.72) | 0.889 | ||
| Sodium Normalization (N vs. Y) | 1.81 (1.01−3.31) | 0.047 | 1.96 (1.05−3.66) | 0.035 |
Significant values are reported in bold.
AC = Adenocarcinoma; CI = confidence interval; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; EGFR = Epidermal growth factor receptor; F = female; HR = hazard ratio; M = male; MT = mutated status; WT = wild-type status